Pfizer RSV vaccine lags GSK's as head-to-head competition underway

GSK accounts for close to two-thirds of RSV shots given in the United States since early September, according to IQVIA data seen by Reuters. The British drugmaker's early advantage may be tied to its positioning as the lone RSV shot offered by CVS Health, the biggest pharmacy chain in the U.S. and a dominant player in the retail vaccine market, analysts and industry experts say.